BI Asset Management Fondsmaeglerselskab A S Sells 60,982 Shares of Gilead Sciences, Inc. $GILD

BI Asset Management Fondsmaeglerselskab A S lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 477,987 shares of the biopharmaceutical company’s stock after selling 60,982 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Gilead Sciences were worth $53,057,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after buying an additional 1,893,401 shares during the period. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after acquiring an additional 727,515 shares in the last quarter. Norges Bank bought a new stake in Gilead Sciences in the second quarter valued at about $2,150,268,000. Invesco Ltd. raised its position in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Finally, Amundi raised its position in Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after purchasing an additional 1,614,355 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $146.23 on Thursday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a 50 day simple moving average of $126.41 and a 200 day simple moving average of $120.40. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $146.73. The firm has a market cap of $181.42 billion, a P/E ratio of 22.67, a P/E/G ratio of 0.76 and a beta of 0.36.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. HSBC lifted their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Needham & Company LLC boosted their price target on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. BMO Capital Markets upped their price target on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $136.73.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the insider directly owned 103,221 shares of the company’s stock, valued at $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 257,397 shares of company stock worth $33,385,512. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.